Illumina (NASDAQ:ILMN) Stock Rating Lowered by Stephens

Illumina (NASDAQ:ILMN) was downgraded by Stephens from a “strong-buy” rating to a “hold” rating in a report issued on Friday, Zacks reports.

A number of other research analysts have also recently issued reports on the stock. Barclays lifted their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a research report on Wednesday, October 7th. Stifel Nicolaus upped their price objective on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 1st. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Leerink Partners boosted their price target on Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Ten equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $234.41.

Illumina Price Performance

ILMN opened at $269.42 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The company has a market cap of $40.68 billion, a price-to-earnings ratio of 50.26, a price-to-earnings-growth ratio of 3.82 and a beta of 1.41. The stock has a fifty day simple moving average of $242.35 and a two-hundred day simple moving average of $191.10. Illumina has a 12-month low of $94.00 and a 12-month high of $309.35.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts predict that Illumina will post 5.36 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Keith Meister sold 457,858 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 2,061,850 shares of company stock valued at $436,479,102. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ILMN. Fiduciary Financial Advisors bought a new stake in Illumina during the second quarter valued at about $26,000. MCF Advisors LLC increased its position in Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after buying an additional 100 shares in the last quarter. Keating Financial Advisory Services Inc. bought a new position in shares of Illumina in the second quarter worth about $32,000. Rakuten Securities Inc. bought a new position in shares of Illumina in the second quarter worth about $33,000. Finally, Elevation Wealth Partners LLC raised its stake in shares of Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after buying an additional 84 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s upcoming quarterly report could benefit from strong clinical demand, NovaSeq X adoption, new instrument placements, and consumables growth. Analysts also expect year-over-year earnings growth and see potential for an earnings beat, although research-market weakness remains a concern. ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
• Positive Sentiment: The company launched three early-access capabilities for its BioInsight Platform—Workflow Orchestrator, DRAGEN Ultra with dnaAI, and Learning Cohorts. The tools expand Illumina’s AI-driven variant prioritization, sequencing analysis, and genomic-data workflow offerings, potentially increasing the strategic importance of software and data services. How Investors May Respond To Illumina BioInsight AI Rollout
• Neutral Sentiment: Illumina is expected to report quarterly results next week. The event is a major near-term catalyst, with investor attention likely centered on clinical demand, NovaSeq X placements, consumables revenue, and management’s outlook. Illumina Expected to Release Quarterly Earnings on Thursday
• Neutral Sentiment: The consensus price target was raised 19.65% to $250.77, signaling improved analyst expectations, but that target remains below Illumina’s recent trading level and may limit upside if not revised further. Illumina Consensus Price Target Increased
• Negative Sentiment: Stephens downgraded Illumina to Equal Weight, reducing a potential source of buying pressure and reflecting a more cautious view of the stock’s risk-reward profile. Stephens Downgrades Illumina to Equal Weight
• Negative Sentiment: Illumina recently fell alongside Twist Bioscience and other AI- and genomics-related stocks in a broad technology selloff, indicating that sector sentiment—not company-specific news—has also been driving volatility. Twist Bioscience and Illumina Slide as AI and Genomics Stocks Sell Off

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.